share_log

Private Companies Invested in Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Copped the Brunt of Last Week's HK$960m Market Cap Decline

Private Companies Invested in Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Copped the Brunt of Last Week's HK$960m Market Cap Decline

私營公司投資于山東威高股份醫療聚合物有限公司(HKG:1066),承受了上週市值下跌96000萬港幣的主要衝擊
Simply Wall St ·  11/26 06:58

Key Insights

  • The considerable ownership by private companies in Shandong Weigao Group Medical Polymer indicates that they collectively have a greater say in management and business strategy
  • A total of 3 investors have a majority stake in the company with 51% ownership
  • 24% of Shandong Weigao Group Medical Polymer is held by Institutions

A look at the shareholders of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) can tell us which group is most powerful. The group holding the most number of shares in the company, around 46% to be precise, is private companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

As market cap fell to HK$20b last week, private companies would have faced the highest losses than any other shareholder groups of the company.

Let's take a closer look to see what the different types of shareholders can tell us about Shandong Weigao Group Medical Polymer.

big
SEHK:1066 Ownership Breakdown November 25th 2024

What Does The Institutional Ownership Tell Us About Shandong Weigao Group Medical Polymer?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Shandong Weigao Group Medical Polymer does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shandong Weigao Group Medical Polymer's earnings history below. Of course, the future is what really matters.

big
SEHK:1066 Earnings and Revenue Growth November 25th 2024

Shandong Weigao Group Medical Polymer is not owned by hedge funds. Weihai Weigao International Medical Investment Holdings Limited is currently the largest shareholder, with 46% of shares outstanding. In comparison, the second and third largest shareholders hold about 3.2% and 2.2% of the stock.

To make our study more interesting, we found that the top 3 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Shandong Weigao Group Medical Polymer

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our information suggests that Shandong Weigao Group Medical Polymer Company Limited insiders own under 1% of the company. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around HK$41m worth of shares (at current prices). Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

General Public Ownership

With a 29% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shandong Weigao Group Medical Polymer. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Company Ownership

Our data indicates that Private Companies hold 46%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Shandong Weigao Group Medical Polymer , and understanding them should be part of your investment process.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論